Edition:
United Kingdom

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

24.33USD
8:42pm GMT
Change (% chg)

$0.75 (+3.18%)
Prev Close
$23.58
Open
$23.32
Day's High
$24.55
Day's Low
$23.23
Volume
243,327
Avg. Vol
376,306
52-wk High
$31.80
52-wk Low
$13.13

Chart for

About

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly... (more)

Overall

Beta: --
Market Cap(Mil.): $1,043.82
Shares Outstanding(Mil.): 41.74
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock

* EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK

06 Dec 2017

BRIEF-Editas Medicine Announces Offering Of Common Stock

* EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

05 Dec 2017

BRIEF-Editas Medicine announces Q3 loss per share $0.64

* Editas Medicine announces third quarter 2017 results and update

07 Nov 2017

BRIEF-Editas receives EMA's orphan medicinal product designation for EDIT-101

* Editas Medicine receives EMA's orphan medicinal product designation for EDIT-101 for the treatment of LCA10

26 Sep 2017

BRIEF-Editas Medicine Inc initiates clinical natural history study of Leber Congenital Amaurosis type 10

* Editas Medicine Inc - announced that company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10)

12 Sep 2017

BRIEF-Editas Medicine Q2 loss per share $0.65

* Editas Medicine announces second quarter 2017 results and update

09 Aug 2017

BRIEF-Editas Medicine achieves milestone under Juno Therapeutics collaboration

* Editas Medicine achieves milestone under Juno Therapeutics collaboration for technical progress towards overcoming the tumor microenvironment Source text for Eikon: Further company coverage:

09 Aug 2017

Earnings vs. Estimates